1.
Resveratrol and anti-atherogenic effects.
Riccioni, G, Gammone, MA, Tettamanti, G, Bergante, S, Pluchinotta, FR, D'Orazio, N
International journal of food sciences and nutrition. 2015;(6):603-10
Abstract
The role of inflammation and oxidative stress in atherosclerosis development has been increasingly well recognized over the past decade. Inflammation has a significant role at all stages of atherosclerosis, including initiation, progression and plaque formation. Resveratrol is a naturally occurring polyphenolic compound found in grape products, berry fruits and red wine. Its ability to behave therapeutically as a component of red wine has attracted wide attention. Accumulating evidence suggests that it is a highly pleiotropic molecule that modulates numerous targets and molecular functions. Epidemiological studies indicate that the Mediterranean diet, rich in resveratrol, is associated with a reduced risk of atherosclerosis. Resveratrol is believed to decrease circulating low-density lipoprotein cholesterol levels, reduce cardiovascular disease risk; it reduces lipid peroxidation, platelet aggregation and oxidative stress. Resveratrol is considered a safe compound, since no significant toxic effects have been demonstrated after administration of a broad range of concentrations, and an effective anti-atherogenic agent.
2.
[From the Point of View of Health Evaluation and Promotion (Ningen Dock) Facilities].
Yamashita, T, Funatsu, K, Kondo, S, Yokoyama, M, Mizuno, K, Nakamura, H
Rinsho byori. The Japanese journal of clinical pathology. 2014;(9):892-4
Abstract
Since the direct method of LDL measurement is easy and convenient, many health evaluation and promotion facilities adopted it without sufficient discussion after specific health checkups started in Japan. For the purpose of reliable, specific health checkup data, we must review the methods and standardization of LDL measurement. I hope that medical societies, the Ministry of Health, Labour and Welfare, and reagent manufacturers will collaborate.
3.
[Chronic liver disease and arteriosclerosis].
Mawatari, S, Uto, H, Tsubouchi, H
Nihon rinsho. Japanese journal of clinical medicine. 2011;(1):153-7
Abstract
The liver is the main metabolic organ of the body and is strongly associated with lifestyle-related diseases in which abnormal metabolism of glucose and lipid are the main manifestations. Recently, the prevalence of nonalcoholic fatty liver disease(NAFLD), including nonalcoholic steatohepatitis (NASH), has been increasing due to a higher rates of obesity. It has been reported that the presence of NAFLD/NASH and associated liver dysfunction are predictors for cardiovascular disease. In addition, attention has been paid to the link between chronic hepatitis C and lifestyle-related diseases such as obesity and insulin resistance. Atherosclerosis is an important risk factor for cardiovascular disease and is associated with lifestyle-related diseases. Thus, chronic liver disease seems to be strongly associated with atherosclerosis. Cardiovascular disease induced by atherosclerosis should be attended to along with liver cirrhosis and hepatocellular carcinoma, and medications for lifestyle-related diseases are needed in patients with chronic liver disease.
4.
[Lifestyle-related diseases and H. pylori].
Suzuki, H, Matsuzaki, J, Hibi, T
Nihon rinsho. Japanese journal of clinical medicine. 2009;(12):2366-71
Abstract
H. pylori infection elicits a chronic cellular inflammatory response not only in the gastric mucosa, but also in the extra-digestive organs. Indeed, H. pylori infection has been epidemiologically linked to the extra-digestive conditions and diseases. In this article, we review recent progress in our understanding about the relationship between H. pylori infection and lifestyle-related diseases, such as atherosclerosis, diabetes mellitus, obesity, hyperlipidemia, hypertension, and osteoporosis. Although the relationships between all of these diseases and H. pylori infection are still controversial, H. pylori infection may increase the risk for cardiovascular and cerebrovascular diseases, especially when CagA+ cytotoxic strains of H. pylori are present.